Abstract
Chemical modification of dipeptide mimetic azatyrosine led to a series of piperazinediones. Thirteen piperazinediones were synthesized and tested for their anticancer activity. This series of piperazinedione compounds exhibited potent anticancer activities against human disease-oriented cancer cell lines in NCI60 cancer screening (National Cancer Institute, USA). Among them, four leads (compound 10, 18, 21, and 22) exhibited in vitro tumor growth suppression, reducing tumor cell growth to 45.7%-56.3%, and exhibited broad-spectrum activities. Compound 18, with 50% cancer cell growth inhibition (GI50)
| Original language | English |
|---|---|
| Pages (from-to) | 4013-4020 |
| Number of pages | 8 |
| Journal | Anticancer Research |
| Volume | 34 |
| Issue number | 8 |
| Publication status | Published - Aug 1 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Azatyrosinamide
- COMPARE algorithm
- DTP
- In vivo antitumor activity
- Mechanism of action prediction
- NCI-60 anticancer screening
- NCI/NIH
- Piperazinediones
- Tubulin polymerization inhibitor
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Novel piperazinediones as antitumor agents'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS